4D Pharma PLC - Leeds-based pharmaceutical firm - Notes cancellation of its shares on AIM from Thursday, after it entered into administration in June 2022. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - 4D Pharma PLC on Friday said it was seeking shareholder approval for a USD15.0 million cash raise, as it works to lift its suspension and restore its shares to trading. Read More
(Alliance News) - 4D Pharma PLC said on Wednesday that its Blautix phase 2 clinical trial results showed the treatment had a positive effect on sufferers of irritable bowel syndrome Read More
4D Pharma PLC - Leeds, England-based pharmaceutical company - Releases its publication of pre-clinical research on mice regarding live biotherapeutic MRx0006 for the treatment of autism spectrum disorder. Says research shows LBP MRx0006 can attenuate core behavioural deficits in a mouse model of autism, improving social deficits, repetitive and anxiety-like behaviours. "Mechanistically, MRx0006 increased in the brains of ASD mice the expression of neuropeptide hormones known to regulate social and anxiety behaviour," 4D Pharma adds. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Friday and not separately reported by Alliance News: Read More
4D Pharma PLC - Leeds, England-based pharmaceutical company - Says it has received written notice from the Nasdaq Stock Market that its securities will be delisted from Nasdaq. Accordingly, trading of its shares will be suspended from the opening of business on July 7. Nasdaq staff cited 4D's announcement that it had been placed into administration on Friday as raising "public interest concerns". The exchange also mentioned concerns regarding the residual equity interest of existing shareholders of listed securities. Read More
4d Pharma PLC - Leeds, England-based pharmaceutical company - Says it has "no immediate certainty" of how it will repay the USD13.9 million loan facility it has with Oxford Finance LLC. Read More
4d Pharma PLC - Leeds, England-based pharmaceutical company - Says it has ordered an immediate suspension of trading in the company's shares on AIM pending a further announcement. Read More
4D Pharma PLC - Leeds, England-based pharmaceutical company - Plans to conduct a phase II study to assess the safety of MRx0518 in combination with Bavencio. Says the study will be conducted in patients with unresectable locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. Says previous data about MRx0518 supports the potential of this combination to "significantly enhance and improve" outcomes for patients, beyond treatment with Bavencio alone. Bavencio is an antibody medication for the treatment of urothelial carcinoma. Read More
4D Pharma PLC - Leeds, England-based pharmaceutical company - Says part A of the phase I/II trial of MRx-4DP0004 for the treatment of asthma showed that a greater amount of patients receiving the drug than those receiving placebo experienced a reduction in asthma control questionnaire scores. Reports that a greater proportion of the MRx-4DP0004 group than the placebo group experienced a reduction in the total weekly use of rescue medication at all time points. Adds that 50% of patients receiving the drug experienced "clinically meaningful" improvements in asthma quality of life questionnaire scores. Says MRx-4DP0004 is progressing to part B of the trial. Plans to enrol asthma patients with more symptomatic disease. Expects this to give a greater scope for treatment effects to be observed. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More
4D Pharma PLC - Leeds, England-based pharmaceutical company - Posts widened pretax loss for 2021. Pretax loss stretches to GBP57.5 million from GBP30.3 million the year before. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday. Read More
(Alliance News) - 4d Pharma PLC shares soared on Wednesday after the company said that its phase I/II study for the combination of MRx0518 and Keytruda for the treatment of renal cell carcinoma showed positive results. Read More
4D Pharma PLC - Leeds, England-based pharmaceutical company - Files shelf registration statement to the US Securities & Exchange Commission following which the company may offer up to USD150.0 million of shares in the form of American Depositary Shares, with each ADS reflecting eight ordinary shares. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More